In a recent Abzena article, Brett Verstak of Abzena and Jonathan Frampton of ProteoNic dive into the innovation behind AbZelectPRO™ — a next-generation cell line development platform built for speed, stability, and scalability.

The discussion explores how AbZelectPRO™, the result of a collaboration between Abzena and ProteoNic, combines a highly optimised CHO-K1 host cell line with ProteoNic’s 2G UNic® vector to accelerate the development of high-yield, genetically stable cell lines — including for complex and difficult-to-express proteins.

As Brett highlights, a key enabler in the platform is Cyto-Mine®, Sphere Bio’s picodroplet-based microfluidic technology. Integrated directly into AbZelectPRO™, Cyto-Mine® plays a critical role in screening and selecting high-performing clones earlier in the process.

“One unique thing to our platform is an instrument called Cyto-Mine®. It encapsulates single cells into picodroplets, so we can measure productivity early, then gate and print those cells into well plates to assess monoclonality. It’s a key part of how we reduce timelines while still ensuring high clonal titers and genetic stability.”

Brett Verstak, Director of Cell Line Development, Abzena

This integration is helping Abzena deliver development timelines as short as 10 weeks, while enabling studies that support IND submissions with greater reliability and flexibility across biologics formats.

Watch the full video interview:

For more insights on the latest developments in biologics and cell line research, visit our Knowledge Hub or or explore our Cyto-Mine® Chroma solution for early-stage screening.

This article is part of our Editorial Coverage series, showcasing thought leadership and technological contributions in top-tier industry publications. Stay tuned for more.